Lessing, Charon; Ashton, Toni; Davis, Peter - In: Applied Health Economics and Health Policy 12 (2014) 5, pp. 537-546
Switching from brand to generic lamotrigine is largely devoid of adverse health outcomes; however, creating an incentive to ensure a greater proportion of patients switch to generic lamotrigine is required to achieve maximal financial savings from a policy of generic reference pricing. </AbstractSection>...
